Cytek Biosciences Q2 2026 revenue up, loss widens

Cytek Biosciences reported second quarter 2026 revenue of $48.1 million, a 6% increase from the second quarter of 2025, driven by strong instrument growth in the U.S. and China and continued expansion of service revenue.

Rhea-AI Filing Summary

Cytek Biosciences reported second quarter 2026 revenue of $48.1 million, a 6% increase from the second quarter of 2025, driven by strong instrument growth in the U.S. and China and continued expansion of service revenue. GAAP gross profit was $28.3 million, up 19% year-over-year, with GAAP gross margin improving to 59%, or 53% excluding a one-time tariff refund. Adjusted gross margin was 61%, or 56% excluding the refund.

Operating expenses rose 15% to $39.7 million, including research and development of $9.7 million, sales and marketing of $13.2 million, and general and administrative expenses of $16.8 million, the latter up 24% due to litigation-related expenses, severance and personnel costs. Loss from operations was $11.4 million, and net loss widened to $12.2 million from $5.6 million a year earlier. Adjusted EBITDA moved to a $1.5 million loss from positive $1.3 million in the prior-year quarter.

Cash, cash equivalents and marketable securities totaled $262.0 million as of June 30, 2026, compared to $262.2 million as of March 31, 2026. For full-year 2026, Cytek now expects revenue between $207 million and $212 million, raising the midpoint of its outlook by $1 million, assuming no change in current foreign currency exchange rates.

Positive

• Gross margin expanded meaningfully, with GAAP gross margin at 59% versus 52% a year earlier and non-GAAP adjusted gross margin at 61% versus 56%, reflecting improved profitability on sales even before considering the one-time tariff refund.
• The company raised 2026 revenue guidance, now expecting $207–$212 million and increasing the midpoint by $1 million, signaling higher anticipated full-year demand under current foreign currency assumptions.

Negative

• Q2 2026 net loss widened to $12.2 million from $5.6 million in Q2 2025, driven by higher operating expenses and reduced other income, indicating significantly weaker bottom-line performance despite revenue growth.
• Q2 2026 adjusted EBITDA turned negative, with a $1.5 million loss compared to positive adjusted EBITDA of $1.3 million a year earlier, showing deterioration in underlying operating profitability.
• General and administrative expenses increased 24% year-over-year to $16.8 million in Q2 2026, reflecting litigation-related expenses, severance and personnel costs that weighed on overall earnings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Q2 2026 Revenue: $48.1 million GAAP Gross Margin: 59% Q2 2026 Net Loss: $12.2 million +4 more

7 metrics

Q2 2026 Revenue $48.1 million Three months ended June 30, 2026; 6% increase compared to Q2 2025

GAAP Gross Margin 59% Second quarter 2026 GAAP gross margin vs 52% in the second quarter of 2025

Q2 2026 Net Loss $12.2 million Net loss in the second quarter of 2026 compared to $5.6 million in Q2 2025

Q2 2026 Adjusted EBITDA ($1.5 million) Adjusted EBITDA loss in Q2 2026 vs positive adjusted EBITDA of $1.3 million in Q2 2025

Cash, Cash Equivalents and Marketable Securities $262.0 million Total as of June 30, 2026 compared to $262.2 million as of March 31, 2026

2026 Revenue Outlook Range $207 million – $212 million Full-year 2026 revenue guidance; midpoint raised by $1 million

Total Assets $446,934 In thousands; total assets as of June 30, 2026 on the consolidated balance sheet

Key Terms

Adjusted EBITDA, Full Spectrum Profiling, deferred revenue, stock-based compensation, +1 more

5 terms

Adjusted EBITDA financial

"Non-GAAP adjusted EBITDA excluding investment income"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

Full Spectrum Profiling technical

"utilizing its patented Full Spectrum Profiling™ (FSP®) technology"

Full spectrum profiling is a comprehensive analysis that measures many types of biological signals—such as genes, proteins, metabolites and other markers—across a sample to build a broad, detailed molecular picture. For investors, it matters because that wide-ranging view can uncover new drug targets, improve predictions of which therapies will work, and support products that personalize care, much like scanning an entire toolbox instead of checking a single tool.

deferred revenue financial

"Deferred revenue, current and Deferred revenue, noncurrent"

Cash a company has already received for goods or services it has promised but not yet delivered; it's recorded as a liability because the company still owes that product, service, or future revenue recognition. For investors, deferred revenue signals upcoming work or deliveries that will convert into reported sales over time and affects short-term obligations, cash flow quality, and how quickly a firm can grow recognized revenue—think of it like prepaid subscriptions or gift cards a business must honor later.

stock-based compensation financial

"after adjusting for stock-based compensation expense and amortization"

Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.

legal settlement liability financial

"Legal settlement liability, current and Legal settlement liability, noncurrent"

Earnings Snapshot

Revenue: $48.1 million · Guidance included

three months ended June 30, 2026

Revenue $48.1 million 6% increase compared to the second quarter of 2025

GAAP gross margin 59% up from 52% in the second quarter of 2025

Net loss $12.2 million compared to $5.6 million in the second quarter of 2025

Adjusted EBITDA ($1.5 million) compared to positive adjusted EBITDA of $1.3 million in Q2 2025

2026 revenue outlook $207 million–$212 million midpoint raised by $1 million for full-year 2026

Guidance

Cytek expects full-year 2026 revenue between $207 million and $212 million, assuming no change in current foreign currency exchange rates.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Cytek Biosciences’ (CTKB) Q2 2026 revenues and growth?

Cytek Biosciences generated $48.1 million in total revenue in Q2 2026, a 6% increase over Q2 2025. Growth was driven by strong instrument sales in the U.S. and China and continued expansion of the company’s service business.

How profitable was Cytek Biosciences (CTKB) in Q2 2026?

Cytek reported a net loss of $12.2 million in Q2 2026 versus a $5.6 million loss a year earlier. Loss from operations was $11.4 million, and adjusted EBITDA shifted to a $1.5 million loss from positive $1.3 million in Q2 2025.

How did Cytek Biosciences’ (CTKB) margins change in Q2 2026?

GAAP gross margin improved to 59% in Q2 2026 from 52% in Q2 2025, while adjusted gross margin rose to 61% from 56%. Excluding a one-time tariff refund, GAAP and adjusted gross margins were 53% and 56%, respectively.

What is Cytek Biosciences’ (CTKB) 2026 revenue outlook?

For full-year 2026, Cytek expects revenue between $207 million and $212 million, raising the midpoint by $1 million. This outlook assumes no change in current foreign currency exchange rates and reflects management’s updated demand expectations.

What is Cytek Biosciences’ (CTKB) cash position as of June 30, 2026?

As of June 30, 2026, Cytek held $262.0 million in cash, cash equivalents and marketable securities, compared with $262.2 million as of March 31, 2026, indicating a relatively stable liquidity position over the quarter.

Why did Cytek Biosciences’ (CTKB) operating expenses rise in Q2 2026?

Operating expenses increased 15% year-over-year to $39.7 million in Q2 2026. Research and development and sales and marketing grew, while general and administrative expenses rose 24% due to litigation-related expenses, severance and personnel costs.

How did Cytek Biosciences’ (CTKB) non-GAAP metrics trend in Q2 2026?

Non-GAAP adjusted gross margin was 61% in Q2 2026, up from 56% a year earlier. Non-GAAP adjusted EBITDA was a loss of $1.5 million, versus positive $1.3 million in Q2 2025, and excluding investment income it was a $2.9 million loss.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 04:22 PM Accepted by SEC EDGAR 08/05/2026 - 04:22 PM Learn about SEC filing dates

false 0001831915 0001831915 2026-08-05 2026-08-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 5, 2026

Cytek Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40632		47-2547526
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

47215 Lakeview Boulevard
Fremont, California		94538
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (877) 922-9835

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		CTKB		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 5, 2026, Cytek Biosciences, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. The press release is being furnished as Exhibit 99.1.

The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description of Exhibit
99.1		Press release dated August 5, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Cytek Biosciences, Inc.
Date: August 5, 2026				By:		/s/ Wenbin Jiang
						Wenbin Jiang, Ph.D. President and Chief Executive Officer

Exhibit 99.1

Cytek Biosciences Reports Second Quarter 2026 Financial Results

FREMONT, Calif., August 5, 2026 (GLOBE NEWSWIRE) – Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2026.

Recent Highlights

• Total revenue for the second quarter of 2026 was $48.1 million, representing a 6% increase compared to the second quarter of 2025

• Launched Cytek Borealis^™, a new 7-laser full spectrum flow cytometer with new and proprietary reagents enabling high-resolution 60-color panels

• Introduced Cytek Aurora^™ Evo instrument configurations with expanded automation capabilities for highly automated lab environments

• Total recurring revenue, comprised of service and reagent revenues, reached $18.5 million in the second quarter. On a trailing-12-month basis, recurring revenue represented 35% of total revenue, up from 32% on a trailing-12-month basis as of the second quarter of 2025

• Expanded to a total installed base of 3,933 Cytek instruments, adding 142 units in the second quarter of 2026

• Updates full year 2026 total revenue guidance to $207 million to $212 million, raising the midpoint by $1 million

“Our second quarter results reflect continued execution against our strategic priorities, exemplified by strong double-digit revenue growth in instruments in the U.S. and in China and ongoing and consistent expansion of our service business,” said Wenbin Jiang, CEO of Cytek Biosciences. “Looking ahead, our priorities remain clear: accelerating adoption of our instrument platforms, including newly launched instruments, expanding recurring revenue business and extending our technology leadership. We believe our investments in products, people, and operations position Cytek well for the remainder of 2026 and the long-term opportunity ahead.”

Second Quarter 2026 Financial Results

Total revenue for the second quarter of 2026 was $48.1 million, a 6% increase compared to the second quarter of 2025. The increase in revenue was driven by strong instrument growth in the U.S. and in China, and continued growth in service.

GAAP gross profit was $28.3 million for the second quarter of 2026, a 19% increase compared to the second quarter of 2025. GAAP gross profit margin was 59% in the second quarter of 2026 compared to 52% in the second quarter of 2025. Adjusted gross profit margin, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles, was 61% in the second quarter of 2026 compared to 56% in the second quarter of 2025. Excluding the impact of a one-time tariff refund, GAAP and adjusted gross margin in the second quarter of 2026 were 53% and 56%, respectively.

Operating expenses were $39.7 million for the second quarter of 2026, a 15% increase compared to the second quarter of 2025 due to increased research and development, sales and marketing, and general and administrative expenses.

Research and development expenses were $9.7 million for the second quarter of 2026, a 10% increase compared to the second quarter of 2025.

Sales and marketing expenses were $13.2 million for the second quarter of 2026, a 9% increase compared to the second quarter of 2025.

General and administrative expenses were $16.8 million for the second quarter of 2026, a 24% increase compared to the second quarter of 2025 due to litigation-related expenses, severance and personnel costs.

Loss from operations in the second quarter of 2026 was $11.4 million compared to loss from operations of $10.6 million in the second quarter of 2025. Net loss in the second quarter of 2026 was $12.2 million compared to a net loss of $5.6 million in the second quarter of 2025.

Adjusted EBITDA loss in the second quarter of 2026 was $1.5 million compared to positive adjusted EBITDA of $1.3 million in the second quarter of 2025, after adjusting for stock-based compensation expense, foreign currency exchange impacts and a write-off of an investment in an early-stage technology company.

Cash, cash equivalents and marketable securities totaled $262.0 million as of June 30, 2026, compared to $262.2 million as of March 31, 2026, a decrease of $0.2 million.

2026 Outlook

Cytek Biosciences is updating its revenue outlook for the full year 2026 to be in the range of $207 million to $212 million, raising the midpoint by $1 million, assuming no change in current foreign currency exchange rates.

Webcast Information

Cytek will host a conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the conference call can be accessed at investors.cytekbio.com.

About Cytek Biosciences, Inc.

Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling^™ (FSP^®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora^™, Northern Lights^™, Cytek Aurora^™ CS and Cytek Aurora^™ Evo systems; the Cytek Orion^™ reagent cocktail preparation system; the Enhanced Small Particle^™ (ESP^™) detection technology; the flow cytometers and imaging products under the Amnis^® and Guava^® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.

Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).

Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Cytek Borealis, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution for information about the company, its products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Certain information disseminated through these channels may be material to investors, and Cytek may use these channels to disseminate such information in accordance with Regulation FD and other applicable disclosure requirements. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Statement Regarding Use of Non-GAAP Financial Information

Cytek has presented certain financial information in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and also on a non-GAAP basis for the three-month period ended June 30, 2026 and June 30, 2025. Management believes that non-GAAP financial measures, including “Adjusted gross profit,” “Adjusted gross profit margin,” “Adjusted EBITDA” and “Adjusted EBITDA excluding investment income,” referenced in this release, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, without limitation, statements regarding Cytek’s business strategies, market opportunities, product plans and expectations, and continued investment in its products, people, and infrastructure; Cytek’s expanding installed base and future recurring revenue growth in its service and reagent businesses; and Cytek’s future financial performance, including its outlook for fiscal year 2026 and expectations for 2026 total revenue. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or

achievements to be materially different from the information expressed or implied by these forward-looking statements. In addition, new risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek’s ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek’s ability to evaluate its prospects for future viability and predict future performance; Cytek’s ability to accurately forecast customer demand and adoption of its products; Cytek’s ability to recognize the anticipated benefits of collaborations; Cytek’s dependence on certain sole and single source suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek’s ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek’s ability to increase penetration in its existing markets and expand into adjacent markets; Cytek’s ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek’s ability to successfully develop and introduce new products; Cytek’s ability to maintain, protect and enhance its intellectual property; Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section titled “Risk Factors” set forth in Cytek’s most recent Quarterly Report on Form 10-Q filed with the SEC on May 7, 2026, Cytek’s Quarterly Report on Form 10-Q to be filed with the SEC on or about the date hereof and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are applicable only as of the date on which they are made, and Cytek does not assume any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s views as of any date subsequent to the date of this press release. Information contained on, or that is referenced or can be accessed through, our website does not constitute part of this document and inclusions of any website addresses herein are inactive textual references only.

Media Contact:

Stephanie Olsen

Lages & Associates

(949) 453-8080

stephanie@lages.com

Investor Contact:

Mark Meehan

Cytek Biosciences

mmeehan@cytekbio.com

Cytek Biosciences, Inc.

Consolidated Balance Sheets

(Unaudited)

(In thousands, except share and per share data)		June 30, 2026				December 31, 2025
Assets
Current assets:
Cash and cash equivalents		$	73,846			$	90,853
Marketable securities			188,158				170,676
Trade accounts receivable, net			49,698				62,509
Inventories			52,251				48,428
Prepaid expenses and other current assets			13,978				19,530
Total current assets			377,931				391,996
Property and equipment, net			20,801				18,009
Operating lease right-of-use assets			10,962				11,315
Goodwill			16,690				16,697
Intangible assets, net			14,865				16,821
Other noncurrent assets			5,685				6,704
Total assets		$	446,934			$	461,542
Liabilities and stockholders’ equity
Current liabilities:
Trade accounts payable		$	8,408			$	6,410
Legal settlement liability, current			2,353				2,495
Accrued expenses			23,855				23,417
Other current liabilities			20,513				16,978
Deferred revenue, current			29,206				28,504
Total current liabilities			84,335				77,804
Legal settlement liability, noncurrent			6,368				6,786
Deferred revenue, noncurrent			18,058				18,339
Operating lease liability, noncurrent			13,517				14,042
Long-term debt			246				525
Other noncurrent liabilities			2,456				2,307
Total liabilities			124,980				119,803
Stockholders’ equity:
Common stock, $0.001 par value; 1,000,000,000 authorized shares as of June 30, 2026 and December 31, 2025, respectively; 129,982,753 and 128,550,136 issued and outstanding shares as of June 30, 2026 and December 31, 2025, respectively			130				129
Additional paid-in capital			451,846				441,107
Accumulated deficit			(132,761	)			(101,738	)
Accumulated other comprehensive income			2,739				2,241
Total stockholders’ equity			321,954				341,739
Total liabilities and stockholders’ equity		$	446,934			$	461,542

Cytek Biosciences, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

		Three months ended June 30,								Six months ended June 30,
(In thousands, except share and per share data)		2026				2025				2026				2025
Revenue, net:
Product		$	32,556			$	31,415			$	61,335			$	59,525
Service			15,584				14,187				30,940				27,534
Total revenue, net			48,140				45,602				92,275				87,059
Cost of sales:
Product			12,884				14,921				28,805				30,450
Service			6,916				6,814				13,876				12,585
Total cost of sales			19,800				21,735				42,681				43,035
Gross profit			28,340				23,867				49,594				44,024
Operating expenses:
Research and development			9,741				8,826				19,345				18,550
Sales and marketing			13,174				12,134				24,820				24,643
General and administrative			16,825				13,531				35,292				26,429
Total operating expenses			39,740				34,491				79,457				69,622
Loss from operations			(11,400	)			(10,624	)			(29,863	)			(25,598	)
Other income (expense):
Interest expense			(281	)			(414	)			(543	)			(705	)
Interest income			819				555				1,606				1,063
Other income (expense), net			(781	)			3,708				(216	)			7,199
Total other income (expense), net			(243	)			3,849				847				7,557
Loss before income taxes			(11,643	)			(6,775	)			(29,016	)			(18,041	)
Provision for (benefit from) income taxes			515				(1,192	)			2,008				(1,056	)
Net loss		$	(12,158	)		$	(5,583	)		$	(31,024	)		$	(16,985	)
Net loss, basic and diluted		$	(12,158	)		$	(5,583	)		$	(31,024	)		$	(16,985	)
Net loss per share, basic		$	(0.09	)		$	(0.04	)		$	(0.24	)		$	(0.13	)
Net loss per share, diluted		$	(0.09	)		$	(0.04	)		$	(0.24	)		$	(0.13	)
Weighted-average shares used in calculating net loss per share, basic			129,460,518				126,934,294				129,084,814				127,632,999
Weighted-average shares used in calculating net loss per share, diluted			129,460,518				126,934,294				129,084,814				127,632,999
Comprehensive loss:
Net loss		$	(12,158	)		$	(5,583	)		$	(31,024	)		$	(16,985	)
Foreign currency translation adjustment, net of tax			517				603				845				43
Unrealized loss on marketable securities			(147	)			(33	)			(348	)			(98	)
Net comprehensive loss		$	(11,788	)		$	(5,013	)		$	(30,527	)		$	(17,040	)

Cytek Biosciences, Inc.

Reconciliation of GAAP to Non-GAAP Measures

(Unaudited)

		Three Months Ended								Six Months Ended
(In thousands)		June 30, 2026				June 30, 2025				June 30, 2026				June 30, 2025
GAAP gross profit		$	28,340			$	23,867			$	49,594			$	44,024
Stock based compensation		$	736			$	1,110			$	1,465			$	2,196
Amortization of acquisition-related intangible assets		$	490			$	481			$	984			$	974
Non-GAAP adjusted gross profit		$	29,566			$	25,458			$	52,043			$	47,194
GAAP gross margin			59	%			52	%			54	%			51	%
Non-GAAP adjusted gross margin			61	%			56	%			56	%			54	%
GAAP net income		$	(12,158	)		$	(5,583	)		$	(31,024	)		$	(16,985	)
Depreciation and amortization		$	2,985			$	2,988			$	5,797			$	5,869
Provision for (benefit from) income taxes		$	515			$	(1,192	)		$	2,008			$	(1,056	)
Interest income		$	(819	)		$	(555	)		$	(1,606	)		$	(1,062	)
Interest expense		$	281			$	414			$	543			$	705
Foreign currency exchange loss (gain)		$	729			$	(1,593	)		$	1,881			$	(2,871	)
Stock based compensation		$	5,339			$	6,791			$	10,200			$	13,420
Write-off Investment		$	1,587			$	—			$	1,587			$	—
Non-GAAP adjusted EBITDA		$	(1,541	)		$	1,270			$	(10,614	)		$	(1,980	)
Investment income		$	(1,383	)		$	(2,048	)		$	(3,012	)		$	(4,309	)
Non-GAAP adjusted EBITDA excluding investment income		$	(2,924	)		$	(778	)		$	(13,626	)		$	(6,289	)

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EX-99.1 126.6 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 16.8 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 10.6 KB